Catestatin (rat) (Rat chromogranin A367-387) is a potent, reversible, noncompetitive, and noncooperative nicotinic cholinergic antagonist derived from chromogranin A (A367-387). Catestatin (rat) inhibits norepinephrine release in rat PC12 pheochromocytoma cells (IC50 = 1.2 µM), and blocks desensitization of norepinephrine release (IC50 = 0.62 µM). Catestatin (rat) exerts antiadrenergic effects through the endothelial PI3K-AKT-eNOS pathway in rat papillary muscles and isolated cardiomyocytes. Catestatin (rat) maintains mitochondrial membrane potential in I/R cardiomyocytes and increases phosphorylation of AKT at S473, GSK3beta at S9, PLB at T17, and eNOS at S1179. Catestatin (rat) reverses desensitization of 22Na+ uptake. Catestatin (rat) can be used for the study of nicotinic cholinergic receptor regulation and catecholamine release control mechanisms[1][2].
Molecular Weight:
2453.82
Formula:
C109H173N35O28S
Target:
Akt,nAChR
Application Notes:
MCE Product type: Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
